Orkin C., Oka S., Philibert P., Brinson C., Bassa A., Gusev D., Degen O., García J.G., Morell E.B., Tan D.H.S., D'Amico R., Dorey D., Griffith S., Thiagarajah S., St Clair M., Van Solingen-Ristea R., Crauwels H., Ford S.L., Patel P., Chounta V., Vanveggel S., Cutrell A., Van Eygen V., Vandermeulen K., Margolis D.A., Smith K.Y., Spreen W.R. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. The Lancet HIV. April 2021. 8:e185-e196. 10.1016/S2352-3018(20)30340-4
AÑO: 2021; IF: 16.07